



School of Medicine  
University of Missouri

# Dialysis in the Pregnant Patient

Laura Hesemann, MD, MSCI, FASN  
Associate Chief Medical Officer, MU Health Care



---

No financial interests or conflicts of interest to disclose.

No discussions of off-label medications.



# Outline

- 
- Epidemiologic Trends
  - Impact
  - Management of the pregnant dialysis patient



## Patient Preferences

- 
- Increasing desire for pregnancy among women with CKD
    - Increasing maternal age norms
    - Increasing kidney transplants improving fertility
    - Improved outcomes



# Fertility Rates

## Dialysis Patient


- 40.9/1000 pt-yrs
- Increasing

## General Population

- 90/1000 pt-yrs
- Decreasing

# Pregnancy Outcomes CKD vs non-CKD

Maternal and fetal pregnancy outcomes in women with CKD compared to women without CKD






## Maternal outcomes

- Preeclampsia 20%
- Induction of labor 74%
  - Hypertension
  - Preeclampsia
  - Fetal growth restriction
- Cesarean section – 63%

# Infant outcomes in CKD vs non-CKD mothers






## Fetal Outcomes

- Decreased rate of live birth – 73-86%
- If pregnancy occurs prior to start of dialysis – 91%
  - Importance of residual renal function
- Preterm delivery <37 weeks – 80%

# Impact of preterm birth





## Preconception

- Discuss risks
- Timing – Pregnancy prior to initiation of RRT improves live birth rate 63% vs 91%
- Impact on transplantation
  - Increased transfusions
  - Increased allosensitization



# Medications

- No ACEi or ARB
  - ACEi Fetopathy:
    - Low fetal perfusion pressure relies on ATII to maintain GFR
    - Low fetal GFR results tubular dysgenesis and oligohydramnios
- No diuretics
  - Careful fluid management with UF



## Noteworthy points

- $\beta$ -hCG elevated in dialysis patients (renally cleared)
- Dietary changes-
  - Protein intake 1.5-1.8g/kg/day
  - Increased mineral needs – liberal dietary phosphorus
- Additional vitamin needs




## Modality Choice

- Nocturnal HD > Conventional HD > Peritoneal Dialysis

# Adjusting the dialysis prescription

- Time





# Adjusting the dialysis prescription

- Time
  - More dialysis:
    - Higher rate of live birth<sup>1</sup>
    - Higher gestational age<sup>2</sup>
    - Higher birth weight<sup>2</sup>




# Adjusting the dialysis prescription

- Time
  - > 36 hrs/week
- Adequacy target

# Adjusting the dialysis dose

- Time
  - $> 36$  hrs/wk
- Adequacy

	Average	Average	Average
Urea	100 mg/dl	100 mg/dl	100 mg/dl
BUN	35 mg/dl	35 mg/dl	35 mg/dl
*Fisher	100 mg/dl	100 mg/dl	100 mg/dl





# Adjusting the dialysis prescription

- Time
  - >36 hrs/week
- Adequacy target
  - BUN <35



# Adjusting the dialysis prescription

- Time
  - >36 hrs/week
- Adequacy target
  - BUN <35
- Volume Shifts<sup>4</sup>:
  - Increased fetal HR variability
  - Uterine contractions



# Adjusting the dialysis prescription

- Time
  - >36 hrs/week
- Adequacy target
  - BUN <35
- Volume stability
- Heparin



## Hypertension

- Increased risk of preeclampsia, preterm delivery, fetal growth restriction<sup>1</sup>
- No data on outcomes related to target BP in dialysis patients<sup>2</sup>
  - Non-dialysis hypertensive patients: no difference in maternal, fetal, or neonatal outcomes based on diastolic BP



# Managing HTN

## Safe

- Methyldopa
- Labetalol
- Nifedipine
- Hydralazine
- Careful volume control

## Unsafe

- ACE inhibitors
- Angiotensin receptor blockers



## Metabolic bone disease

- Liberal dietary phosphorus and calcium
- Hyperphosphatemia less common
- Phosphorus binders may reduce absorption of fat-soluble vitamins and folate
  - Sevelamer may be unsafe
- VDRA safe in pregnancy
- No safety data for cinacalcet



# Anemia

- ESA safe – do no cross placenta



## Summary

- Women on dialysis increasingly desire pregnancy
- Counsel on high rates of mother and infant morbidity
- BUN < 35 mg/dL
- 36 hrs/week
- Nocturnal hemodialysis best outcomes

